SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc. (FibroGen), today announced the presentation of a Phase 2 subgroup analysis comparing treatment response to roxadustat (FG-4592), a first-in-class oral compound in late stage development, in incident peritoneal dialysis (PD) patients and incident hemodialysis (HD) patients for the treatment of anemia in end stage renal disease (ESRD). This analysis was presented in an oral session at the 2013 American Society of Nephrology (ASN) Kidney Week in Atlanta, Georgia.
Help employers find you! Check out all the jobs and post your resume.
